Roche acquires LumiraDx’s point of care technology for $295m
Roche will pay $295m for the acquisition and up to $55m for funding the business until the deal closes in mid-2024.
02 January 2024
02 January 2024
Roche will pay $295m for the acquisition and up to $55m for funding the business until the deal closes in mid-2024.
The non-invasive, at-home wearable neuromodulation therapy Relivion is designed for treating migraine and depression.
The enhancement will enable the artificial heart Aeson to detect potential malfunctions in real time and control it accordingly.
The clearance adds to existing approvals for improvements in facial aesthetic improvements, tissue lifts, and cellulite.
The Belgian company has submitted a premarket approval application for its already CE-marked device, with FDA approval anticipated by H2 2024.
In clinical evaluations, the test showed to deliver results on the smartphone or mobile device in nearly 30 minutes.
PharmaSens secured ISO 13485 certification for the insulin patch pump system in November 2023.
The company anticipates obtaining FDA approval for the FARAPULSE PFA System in the first quarter of next year.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest thematic report will help you to understand and identify the important themes that threaten to disrupt your business in 2024. Our 2024 theme map covers not only disruptive tech themes but also ESG, macroeconomic, and regulatory themes. Reading this report is the first step towards making better business decisions in 2024.
Give your business an edge with our leading industry insights.